Mustang Bio Gets Second Nasdaq Grace Period to April 12, 2027; Reverse Split on the Table
MBIO is trading near its 52-week low of $0.37 (4.3% above the low).
Summary
Mustang Bio missed its October 12, 2026 deadline to regain Nasdaq's $1.00 minimum bid price and received a second grace period through April 12, 2027. The company says it may effect a reverse stock split to cure the deficiency.
Key Events · Legal and Risk Events · MBIO
-
Second Nasdaq Grace Period Granted
Nasdaq granted an additional 180-calendar day period, extending the bid-price compliance deadline from October 12, 2026 to April 12, 2027.
-
Reverse Split Flagged as Cure
The company notified Nasdaq of its intention to cure the deficiency by effecting a reverse stock split, if necessary.
-
Delisting Risk Remains Live
Failure to regain compliance by April 12, 2027 would trigger a delisting notice; an appeal to the Nasdaq Hearings Panel would not pause any trading suspension.
-
Compliance Requires 10-Day $1.00 Bid
Compliance can be achieved by evidencing a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the second grace period.
Analysis · MBIO · Life Sciences
Mustang Bio failed to regain the $1.00 minimum bid price by its October 12, 2026 deadline, so Nasdaq has granted a second 180-day window running to April 12, 2027. The company told Nasdaq it intends to cure the deficiency with a reverse stock split if needed — a move that would mechanically lift the share price but shrink the share count, and one that comes against a stock trading near its 52-week low of $0.3701. If compliance is not regained by April 12, 2027, Nasdaq will issue a delisting notice; the company could appeal to a Hearings Panel, but an appeal would not pause any trading suspension. This is a stay of execution, not a fix — the delisting risk remains live for another six months.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 30.7% of the 1581 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBIO was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $0.37 to $1.69. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.